Declan Murphy

Urologist & Director of GU Oncology, Peter MacCallum Cancer Centre | Professor, University of Melbourne | Podcasting at GU Cast. Views my own. RT = endorsement

[Declan Murphy @declangmurphy]

@daviesbj For sure! “Exhaustive” list of virtues not an onerous request old mate! Should be able to put away the required minute over the weekend 😉😘

[Declan Murphy @declangmurphy]

Sigh. That sinking feeling when you know the monopolar shears is on its last life 😭#safetyscissors #roboticsurgery

[GU Cast | Urology podcast! @gu_onc]

GU Cast tackles “randomised trials that did not change practice”! Kidney cancer and robotic prostatectomy. With our Journal Club Editors @elena_k_berg @carlosdelgadord and Hosts @RenuEapen @declangmurphy https://t.co/BODmbasw06

[GU Cast | Urology podcast! @gu_onc]

@AshTewariMD joins GU Cast to talk all things nerve-sparing #roboticprostatectomy. And cricket! Fascinating 20yr journey to get to his technique today. Includes surgical footage #prostatecancer @MountsinaiUro @RenuEapen @declangmurphy https://t.co/JkLCXKURpA

[European Urology Oncology @EurUrolOncol]

🎤Our very own @mroupret & @Ric_Campi chats with @declangmurphy and @RenuEapan, hosts of @gu_onc and its spin off, European Urology Podcast.
https://t.co/K97blySTVI or listen wherever you find your podasts
Watch on You Tube: https://t.co/nKpdn5JQIP

📢Papers highlighted in this podcast include:

🩺Expanding Risk-adapted Early Detection of Prostate Cancer: A Call to Action for Men at High Risk by Maike K. Klett...Alicia K. Morgans et al
https://t.co/iA0IhdmcDO

🩺Blood and Urine Circulating Tumor DNA in Urothelial Bladder Cancer: State of the Art and Clinical Perspective by Igor Duquesne...François Audenet et al
https://t.co/4ldBN0Y0P0

🩺Cambridge kidney One-Stop Mass Investigation Clinic (CkOSMIC): A Nonrandomised Feasibility Study by Chiara Re...Grant D. Stewart et al
https://t.co/pVDXuocg1K

🩺Improved Shared Decision-making for Patients with Renal Cell Carcinoma: Results of the SDM-RCC Study by Cato C. Bresser...Paul B. van der Nat et al (for the SDM-RCC Study Group)
https://t.co/2xWwxaeERh

@uroweb
@GPloussard
@jteoh_hk
@CaPsurvivorship
@LauraMarandino
@Ecastromarcos
@OncoAlert
@Sciencedirect

Enjoy!

[Daniel D Eun MD @md_eun]

UAA 2026 in Manila, Philippines! Come join the congress for tips/tricks, updates and the famous hospitality that the Filipinos are known for. It’s going to be a great meeting!

[OncoAlert @OncoAlert]

We warmly invite you to join @OncoAlert 🚨 in Lugano, Switzerland🇨🇭 , from April 29 to May 1, 2027, for #LPCCC27 — the Localized Prostate Cancer Consensus Conference.

👉 https://t.co/hwCK8gdcJt
🔗 Register now and be part of #LPCCC27 in Lugano!

Building on the success and trusted format of APCCC, LPCCC will bring together leading international experts, clinicians, researchers, and patient advocates every other year to address the most important challenges in the diagnosis and clinical management of localized #ProstateCancer

📅 Register early and save!

Take advantage of early-bird rates and exclusive discounts for students, nurses, charity representatives, and participants from LICs and LMICs attending in person.

🌐 Free registration is available for patient representatives, press representatives, and online participants from LICs and LMICs.

Join the global forum shaping the future of localized prostate cancer care!

#ProstateCancer #GUOncology #UroOnc #CancerCare #PrecisionMedicine #Oncology

@Silke_Gillessen
@ProfKHerrmann
@LoebStacy
@declangmurphy
@DrSpratticus
@Tilki_De
@piet_ost
@alison_tree
@AOmlin
@ResearchWyatt
@ckcding
@stefanofanti4

Ping
@nataliagandur
@scocmem
@AmandaNizamMD

[Ash Tewari, MD @AshTewariMD]

A great conversation about ABC of Nerve Sparing robotic prostatectomy with Mr. Declan Murphy and Dr. Rene Eapen. Thanks Declan and Renu for your podcast. https://t.co/CFmXUOaEHk

[Declan Murphy @declangmurphy]

Thanks so much @NehaVapiwala for inviting me to dial into this great @ASTRO_org webinar with @AmarUKishan. I learned a lot! Great to talk multidisciplinary approaches to high-risk prostate cancer

[Declan Murphy @declangmurphy]

7.15am here, patient should be going to sleep. But World Cup final just went to extra time. “Will my prostate cancer deteriorate if we delay 45 min? No” Come on Spain!

[GU Cast | Urology podcast! @gu_onc]

@Uromigos Happy 500th Episode!! @gu_onc salutes you @brian_rini @tompowles1 @RenuEapen @declangmurphy #podcast🎙️🥂

[Shilpa Gupta @shilpaonc]

Happy 4th of July! 🇺🇸
Rounding in hospital today in my cool @gu_onc tee. (Thanks @RenuEapen @declangmurphy )
Wishing everyone a safe, happy, and healthy Independence Day.
@CleClinicMD

[Declan Murphy @declangmurphy]

@DrStish @ChapinMD @TylerSbrt @SeanMcGuireMD @Prof_Nick_James @KOSJ12 @NicholasZaorsky @DrHowardSandler @prostatemd @tjroycemd @PaulSargos @jmmrad @kluwemdphd @weeloonong @BrandonMahal @aleberlin2 @Soum_Roy_RadOnc @drjefstathiou @seanmmcbride @ZilliThomas @docpriyamvada @Xristodouleas @a_dalpra @whallradonc @ndesai2005 @AlisonBirtle @PCaParker @angela_jia_ @rtdess @PBlanchardMD @SbrtSean @subatomicdoc @DrAndrewLoblaw @DrSpratticus @TonyFelefly @shilpa_surasi @UTMDAnderson New generation total body PET/CT with dynamic imaging very useful for BCR. We see the local/nodal recurrence before urinary activity @DrMHofman. Plus novel tracers like Cu-64 PSMA showing great promise in BCR eg Co-PSMA trial @drlouiseemmett

[Michael Hofman @DrMHofman]

First images from the GE Omni 128 cm Total Body PET/CT 🚀

The new scanner detected a <5 mm local recurrence of prostate cancer missed by standard PSMA PET/CT - despite 79% shorter acquisition ⏱️

Delayed imaging boosted lesion uptake and informed dose-painted salvage RT 🎯

@JournalofNucMed @PeterMacCC @declangmurphy @_ShankarSiva
https://t.co/Kiq9PHC12X

[Declan Murphy @declangmurphy]

Quick jump from deep Winter in Melbourne to the hottest day on record in Berlin! Great place to record a GU Cast with old friends @BertrandTOMBAL @SFreedlandMD @gu_onc Coming soon

[European Urology @EUplatinum]

🎙️ The June 2026 European Urology Podcast is here!

Join hosts @declangmurphy and @RenuEapen as they speak with Editor-in-Chief @Albert0Briganti, who highlights three Editor's Choice papers from the June issue and shares his reaction to the newly released Impact Factors. 📈

Editor's Choice papers:

1️⃣ Multiparametric Magnetic Resonance Imaging and Vesical Imaging-Reporting and Data System (VI-RADS) for Bladder Cancer Diagnosis and Staging: A Guide for Clinicians from the American College of Radiology VI-RADS Steering Committee
https://t.co/HKOen91po8

2️⃣ Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group
https://t.co/sC60jG91MQ

🎧 Full GU Cast episode: https://t.co/7eoYSmAvSR

3️⃣ Prospective Comparison of 64Copper [64Cu]SAR-bisPSMA vs 68Gallium [68Ga] PSMA-11 PET/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial)
https://t.co/C9tmXaK8HB

🎧 Full GU Cast episode: https://t.co/jAU8mpnHBX

📚 Explore the full June 2026 issue:
https://t.co/VJu4EBz2gE

🎧 Also available as an audio podcast—search European Urology Podcast wherever you get your podcasts.

The European Urology Podcast is produced by the GU Cast team in Melbourne, Australia.

[Declan Murphy @declangmurphy]

International guests in GU Cast studio already this week:
Tuesday night - @shilpaonc
Wednesday night - @DrRanaMcKay
Two of our all-time favourite GU medical oncologists!
Coming soon on GU Cast! @RenuEapen @gu_onc

[European Urology @EUplatinum]

��� European Urology remains at the top of our field in Nephrology and Urology!

📈 With our Impact Factor rising to 29.1 and more than 2 million article downloads annually, we are constantly striving to be a cut above the rest!

🙏 Thank you to our Authors, Reviewers, and Readership for their continuous support of our journal.

#ImpactFactor #EurUrol #EAU #ACutAboveTheRest

[Declan Murphy @declangmurphy]

GU Oncology MDT been hacked this morning #FIFA #worldcup

[OncoAlert @OncoAlert]

Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial

https://t.co/YivTlLtNTA

In this phase III randomized trial of 660 biopsy-naïve men with high clinical suspicion of prostate cancer but non-suspicious or equivocal MRI findings, ^68Ga-PSMA-11 PET/CT-guided evaluation was non-inferior to standard systematic biopsy for detecting clinically significant #ProstateCancer (12% vs 16%). Importantly, PSMA PET/CT enabled nearly half of participants (49%) to safely avoid biopsy while maintaining diagnostic accuracy.

These findings suggest PSMA PET/CT may refine prostate cancer diagnosis, reducing unnecessary biopsies and associated overdiagnosis.

@ButeauJames
@DrMHofman
@drlouiseemmett
@declangmurphy
@veerukasi
@DrDanielMoon
@DrScottLeslie
@szetinglee1

@montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas @brian_rini @AOmlin

#OncoAlertAF
@nataliagandur @realbowtiedoc @Onco_Cifu88 @scocmem

[GU Cast | Urology podcast! @gu_onc]

Great to see #PRIMARY2 paper in @TheLancetOncol. ICYMI our GU Cast here @ButeauJames @drlouiseemmett @DrDanielMoon @declangmurphy https://t.co/2DoWyrITbO